Published by Josh White on 30th August 2024
(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma, it announced on Friday.
URL: http://www.digitallook.com/dl/news/story/34523201/...